HIF-1αinduces ovarian cancer to resistant to bevacizumab
10.11904/j.issn.1002-3070.2015.04.002
- VernacularTitle:H IF －1α促进卵巢癌贝伐单抗耐药的研究
- Author:
Ge YU
;
Xian YANG
;
Xiaodong LIU
;
Hua SHAO
;
Yulan ZHAO
;
Jing WANG
- Publication Type:Journal Article
- Keywords:
Bevacizumab;
HIF-1α;
Ovarian cancer
- From:
Practical Oncology Journal
2015;(4):294-298
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between HIF-1αand bevacizumab resistant in o-vary cancer,and explore the influence on ovary cancer cell by HIF-1α.Methods The correlation was analyzed between HIF-1αexpression and clinicopathological parameters using immunohistochemistry in 62 patients with ovarian cancer.In addition,the expression of HIF-1αand VEGF were evaluated by real time PCR or Western Blot in SKOV3 and ES-2 cell under CoCl 2 treatment.Results HIF-1αwas overexpressed in cancer tissue, and its high levels were related to CA125(P=0.027)and resistant to bevacizumab(P<0.001).Moreover,CoCl2 could induce high expressions of HIF-1αand VEGF,when compared to normal condition.Conclusion Our findings suggest that HIF-1αis associated with resistant to bevacizumab.It is more chemotherapeutic sensitivity when combined with bevacizumab and HIF-1αantibody.
